Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 12;50(D1):D687–D692. doi: 10.1093/nar/gkab1028

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Comparative analysis of the biological effect of three compounds in atopic dermatitis using ReactomeGSA. The efficacy of Secukinumab, an IL17 inhibitor (GSE137430, transcriptomics) (17), Ustekinumab, an IL23/IL12 inhibitor (GSE140684, microarray) (18), and a JAK/SYK inhibitor (GSE133385, microarray) (19) was each compared with placebo. (A) Correlation analysis shows there is no shared biological effect between the drugs (example Secukinumab versus Ustekinumab). (B) As expected, only the JAK/SYK inhibitor led to a significant down-regulation of inflammatory pathways, consistent with the efficacy (and FDA approval) of only this class of the tested drugs in atopic dermatitis. (C) Comparison of different timepoints of a longitudinal study. The time series analysis of the JAK/SYK inhibitor effect shows earlier down-regulation of MHC signaling, followed by broad down-regulation of T-cell related inflammation.